Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)

Qu'est-ce que Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)?

This rare disease is a congenital genetic condition that presents with a variety of different symptoms affecting multiple parts of the body.

There are just 50 cases diagnosed worldwide, to date.

The main features of the syndrome include intellectual disability, hearing impairment, and digit anomalies.

This syndrome is also known as:
Brachydactyly Due To Absence Of Distal Phalanges DDOD Digitorenocerebral Syndrome Door; Syndrome DOORS; syndrome Drc; Syndrome Eronen;

Quelles sont les causes des changements génétiques Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)?

Les mutations du gène TBC1D24 sont responsables du syndrome. Le syndrome est hérité selon un schéma autosomique récessif.

L'hérédité autosomique récessive signifie qu'un individu affecté reçoit une copie d'un gène muté de chacun de ses parents, ce qui lui donne deux copies d'un gène muté. Les parents qui ne portent qu'une seule copie de la mutation génique ne présenteront généralement aucun symptôme, mais auront 25% de chances de transmettre les copies des mutations génétiques à chacun de leurs enfants.

Quels sont les principaux symptômes de Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)?

The symptoms are mainly congenital and most are present at birth.

The main symptoms of the syndrome include deafness (related to the inner ears), short or absent nails, short fingers and toes as well as intellectual disability and developmental delay.

Seizures are a common symptom of the syndrome and they may take the form of different types of seizures that vary in intensity and severity.

Physical and facial features of the syndrome include a very small head, a wide and fat nose, narrow and high arched palate, and possible dental abnormalities.

Many individuals with the syndrome also have an extra bone and joint in the thumb.

Individuals may also experience heart and urinary tract issues. Low levels of the thyroid hormone may also be a symptom.

Possible clinical traits/features:
Coarse facial features, Malformation of the heart and great vessels, Dandy-Walker malformation, Cystic renal dysplasia, Everted lower lip vermilion, Nail dystrophy, Downturned corners of mouth, Brachydactyly, Prominent nose, Profound sensorineural hearing impairment, High myopia, Microcephaly, Progressive, Muscular hypotonia, Intellectual disability, Anteverted nares, Low-set ears, Long philtrum, Autosomal recessive inheritance, Seizure, Renal agenesis, Optic atrophy, Sensorineural hearing impairment, Hyporeflexia, Abnormality of the skin, High palate, Short distal phalanx of finger, Triphalangeal thumb, Nail dysplasia, Wide nasal bridge, Bulbous nose, Cataract, Anonychia, Cerebral atrophy, Bilateral sensorineural hearing impairment, Blindness

Comment quelqu'un se fait-il tester pour Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)?

Les premiers tests de Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS) peut commencer par un dépistage par analyse faciale, en passant par le FDNA Telehealth plateforme de télégénétique, qui permet d'identifier les marqueurs clés de la syndrome et souligner la nécessité de tests supplémentaires. Une consultation avec un conseiller génétique puis un généticien suivra. 

Sur la base de cette consultation clinique avec un généticien, les différentes options pour les tests génétiques seront partagées et le consentement sera recherché pour des tests supplémentaires.

Informations médicales sur Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation and seizures syndrome (DOORS)

The main features of this severe autosomal recessive condition are contained in the expanded acronym. Some authors have added an S to DOOR, as seizures are a cardinal feature. The head circumference is usually normal at birth. The diagnosis is suggested by looking at the hands and feet. The big toes and thumbs are long, and often have three segments (triphalangy), while the other fingers and toes are short due to an absent or hypoplastic distal phalanx. The nails are absent or poorly formed. The facial features contribute to the diagnosis, especially the bilateral ptosis, short broad nose, the broad nasal tip, and large nostrils which are useful in forming a Gestalt.

Thornton et al., (1994) reported a case with hydronephrosis and hydroureter, and a VSD and secundum ASD. A sib had similar urinary tract anomalies. Reardon et al., (1994) reported a case with abnormal peripheral nerve conduction. The prognosis can be poor and status epilepticus can be a problem.
There are probably at least two distinct forms of this condition, one being dominant and the other recessive, but even these two groups are likely to be heterogeneous.
The entity here refers to sibs such as those described by Feinmesser and Zelig (1961), whose parents were consanguineous. The deafness was sensorineural, congenital but sub-total. Intelligence was thought to be normal. Hair and teeth were normal but the nails on the fingers and toes were rudimentary. See elsewhere for the DOOR syndrome in which retardation is usually profound.
Patton et al., (1987) noted elevated plasma and urinary 2-oxoglutarate in three severely affected unrelated patients. More mildly affected patients have been reported without increased excretion of 2-oxoglutarate (Bos et al., 1994). Note that infants with raised 2-oxoglutarate have been reported where the biochemical abnormality has been a deficiency of alpha-ketoglutarate. These infants have not had the dysmorphic features of DOOR syndrome (Bonnefont et al., 1992).
The condition is probably separate from that described by Goodman (1969) in a dominant family without retardation. Lin et al., (1993) reported a case without convulsions, but with EEG abnormalities, although the child was severely retarded. 2-oxoglutarate excretion was not raised in the urine.
The patient described by Eronen et al., (1985) has DOOR syndrome and excretes large amounts of 2-oxoglutarate (Somer, personal communication, 1991). Likewise, the sibs reported by Le Merrer et al., (1992) most likely have this syndrome (2-oxoglutarate was not measured) - additional features included cataracts, optic atrophy and Dandy-Walker malformation.
The patient reported by Lin et al., (1993) had mild developmental delay and no seizures. However, she did have severe sensorineural deafness and abnormal nails and terminal phalanges. Urinary 2-oxoglutarate excretion was normal.
A 3-generation family was reported by White and Fahey, (2011). Those affected had deafness, nail hypoplasia, hypoplasia of the terminal phalanges, finger-like thumbs and bulbous ends to their fingers.
Surendran et al., (2002) reported four patients from three families with the clinical features of DOOR and increased urinary levels of 2-oxoglutarate. The activity of 2-oxoglutarate in fibroblasts and white blood was decreased. The activity of E1component of the 2-Oxoglutarate dehydrogenase complex in fibroblasts and white blood cells was significantly lower compared to the controls. The condition is well reviewed by James et al., (2007).
Note the case (one of the twins) reported by Mihci et al., (2008) after conception by intracytoplasmic sperm injection. Twenty-six families were included in the study by Campeau et al., (2014). . Eleven persons from nine families had TBC1D24 mutations. Eight did not have seizures and three were not deaf.
Lugano et al., (2016) reported three siblings with compound heterozygous missense mutations in the TBC1D24 gene. Affected males died during infancy while the affected female died at four years of age. The proband also had an abnormal hearing screening.
A male patient with a novel homozygous mutation in the TBC1D24 gene was described by Atli et. al., (2017). An unusual feature was hypochromic microcytic anaemia.

* This information is courtesy of the L M D.
If you find a mistake or would like to contribute additional information, please email us at: [email protected]

Soyez plus rapide et plus précis Diagnóstico Genético!

Plus de 250,000 patients analysés avec succès!
N'attendez pas des années pour un diagnostic. Agissez maintenant et gagnez un temps précieux.

Commencer ici!

"Notre chemin vers un diagnostic de maladie rare a été un voyage de 5 ans que je ne peux décrire que comme une tentative de faire un road trip sans carte. Nous ne connaissions pas notre point de départ. Nous ne connaissions pas notre destination. Maintenant nous avons de l'espoir. "

Image

Paula et Bobby
Parents de Lillie

Qu'est-ce que la FDNA Telehealth?

FDNA Telehealth est une entreprise de santé numérique de premier plan qui offre un accès plus rapide à une Analyse Génétique précise.

Dotée d'une technologie hospitalière recommandée par les plus grands généticiens, notre plateforme unique met les patients en contact avec des Experts En Génétique pour répondre à leurs questions les plus urgentes et clarifier toute préoccupation qu'ils pourraient avoir concernant leurs Symptômes.

Avantages de la FDNA Telehealth

Icône FDNA

Credibility

Notre plateforme est actuellement utilisée par plus de 70% des généticiens et a été utilisée pour diagnostiquer plus de 250,000 patients dans le monde.

Icône FDNA

Accessibilité

FDNA Telehealth fournit une analyse faciale et un dépistage en quelques minutes, suivi d'un accès rapide aux conseillers en génétique et aux généticiens.

Icône FDNA

Facilité d'utilisation

Notre processus transparent commence par un diagnostic initial en ligne par un conseiller en génétique et s'ensuit par des consultations avec des généticiens et des tests génétiques.

Icône FDNA

Précision et précision

Capacités et technologies avancées d'intelligence artificielle (IA) avec un taux de précision de 90% pour une meilleure précision analyse génétique.

Icône FDNA

La valeur pour
De l'argent

Accès plus rapide aux conseillers en génétique, aux généticiens, aux tests génétiques et au diagnostic. En moins de 24 heures si nécessaire. Économisez du temps et de l'argent.

Icône FDNA

Confidentialité et sécurité

Nous garantissons la meilleure protection de toutes les images et informations des patients. Vos données sont toujours sûres, sécurisées et cryptées.

La FDNA Telehealth peut vous rapprocher d'un diagnostic.
Planifiez une réunion de conseil ginitique en ligne dans les 72 heures!

EspañolDeutschPortuguêsFrançaisEnglish